{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:50:56Z","timestamp":1778539856373,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10096-023-04575-z","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T08:15:29Z","timestamp":1676621729000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-2868","authenticated-orcid":false,"given":"Zachary A.","family":"Yetmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan B.","family":"Khodadadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Raymond","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supavit","family":"Chesdachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar M.","family":"Abu Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"4575_CR1","doi-asserted-by":"crossref","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev. [Internet] 2012;25:362\u201386. https:\/\/journals.asm.org\/doi\/10.1128\/CMR.05022-11.10.1128\/CMR.05022-11","DOI":"10.1128\/CMR.05022-11"},{"key":"4575_CR2","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation [Internet] 2015 13;132:1435\u201386. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26373316d.10.1161\/CIR.0000000000000296"},{"key":"4575_CR3","doi-asserted-by":"crossref","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin. Infect. Dis. [Internet] 2011 1;52:e18\u201355. https:\/\/academic.oup.com\/cid\/article\/52\/3\/e18\/306145d.10.1093\/cid\/ciq146","DOI":"10.1093\/cid\/ciq146"},{"key":"4575_CR4","doi-asserted-by":"crossref","unstructured":"Bidell MR, Patel N, O\u2019Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J. Antimicrob. Chemother. [Internet] 2018;73:2643\u201351. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30085140d.10.1093\/jac\/dky259","DOI":"10.1093\/jac\/dky259"},{"key":"4575_CR5","doi-asserted-by":"crossref","unstructured":"Eljaaly K, Alshehri S, Erstad BL. Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin. Antimicrob. Agents Chemother. [Internet] 2018;62. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29437617d.10.1128\/AAC.01816-17","DOI":"10.1128\/AAC.01816-17"},{"key":"4575_CR6","doi-asserted-by":"crossref","unstructured":"Wieland BW, Marcantoni JR, Bommarito KM, Warren DK, Marschall J. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Clin. Infect. Dis. [Internet] 2012 1;54:585\u201390. https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cir857d.10.1093\/cid\/cir857","DOI":"10.1093\/cid\/cir857"},{"key":"4575_CR7","doi-asserted-by":"crossref","unstructured":"Hamad Y, Connor L, Bailey TC, George IA. Outcomes of outpatient parenteral antimicrobial therapy with ceftriaxone for methicillin-susceptible staphylococcus aureus bloodstream infections\u2014a single-center observational study. Open Forum Infect. Dis. [Internet] 2020 1;7. https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa341\/5892290d.10.1093\/ofid\/ofaa341","DOI":"10.1093\/ofid\/ofaa341"},{"key":"4575_CR8","doi-asserted-by":"crossref","unstructured":"Carr DR, Stiefel U, Bonomo RA, Burant CJ, Sims S V. A comparison of cefazolin versus ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia in a tertiary care VA medical center. Open Forum Infect. Dis. [Internet] 2018 1;5. https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy089\/4999397d.10.1093\/ofid\/ofy089","DOI":"10.1093\/ofid\/ofy089"},{"key":"4575_CR9","doi-asserted-by":"crossref","unstructured":"Yetmar ZA, Razi S, Nayfeh T, Gerberi DJ, Mahmood M, Abu Saleh OM. Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis. Int. J. Antimicrob. Agents [Internet] 2022;59:106486. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921013273d.10.1016\/j.ijantimicag.2021.106486","DOI":"10.1016\/j.ijantimicag.2021.106486"},{"key":"4575_CR10","doi-asserted-by":"crossref","unstructured":"Alsowaida YS, Benitez G, Bin Saleh K, Almangour TA, Shehadeh F, Mylonakis E. Effectiveness and safety of ceftriaxone compared to standard of care for treatment of bloodstream infections due to methicillin-susceptible Staphylococcus aureus: a systematic review and meta-analysis. Antibiotics [Internet] 2022 10;11:375. https:\/\/www.mdpi.com\/2079-6382\/11\/3\/375d.10.3390\/antibiotics11030375","DOI":"10.3390\/antibiotics11030375"},{"key":"4575_CR11","doi-asserted-by":"crossref","unstructured":"Heffernan AJ, Sime FB, Lim SMS, Adiraju S, Wallis SC, Lipman J, et al. Pharmacodynamics of ceftriaxone for the treatment of methicillin\u2010susceptible Staphylococcus aureus: is it a viable treatment option? Int. J. Antimicrob. Agents [Internet] 2022;59:106537. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000279d.10.1016\/j.ijantimicag.2022.106537","DOI":"10.1016\/j.ijantimicag.2022.106537"},{"key":"4575_CR12","doi-asserted-by":"crossref","unstructured":"Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J. Antimicrob. Chemother. [Internet] 2018 1;73:1888\u201394. https:\/\/academic.oup.com\/jac\/article\/73\/7\/1888\/4960909d.10.1093\/jac\/dky120","DOI":"10.1093\/jac\/dky120"},{"key":"4575_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"4575_CR14","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"4575_CR15","unstructured":"CLSI. M07 methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically [Internet]. 2018. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m07\/?gclid=CjwKCAiAheacBhB8EiwAItVO2_0Y05lpjahsoOxFT0s4Nj1q0BKZXqSEAuxO6rRXtLvvyoDWJXHLFRoCVlwQAvD_BwE"},{"key":"4575_CR16","doi-asserted-by":"crossref","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. [Internet] 1994;47:1245\u201351. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0895435694901295d.10.1016\/0895-4356(94)90129-5","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"4575_CR17","doi-asserted-by":"crossref","unstructured":"Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. [Internet] 2002 19;137:791\u20137. http:\/\/annals.org\/article.aspx?doi=10.7326\/0003-4819-137-10-200211190-00007d.10.7326\/0003-4819-137-10-200211190-00007","DOI":"10.7326\/0003-4819-137-10-200211190-00007"},{"key":"4575_CR18","doi-asserted-by":"crossref","unstructured":"Barber KE, Cramer RA, Bell AM, Wagner JL, Stover KR. Ceftriaxone as an alternative therapy for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia after initial clearance of bloodstream infection. Case Rep. Infect. Dis. [Internet] 2021 26;2021:1\u20136. https:\/\/www.hindawi.com\/journals\/criid\/2021\/8884685\/d.10.1155\/2021\/8884685","DOI":"10.1155\/2021\/8884685"},{"key":"4575_CR19","doi-asserted-by":"crossref","unstructured":"Patel UC, McKissic EL, Kasper D, Lentino JR, Pachucki CT, Lee T, et al. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. Int. J. Clin. Pharm. [Internet] 2014 4;36:1282\u20139. http:\/\/link.springer.com\/10.1007\/s11096-014-9999-5d.10.1007\/s11096-014-9999-5","DOI":"10.1007\/s11096-014-9999-5"},{"key":"4575_CR20","doi-asserted-by":"crossref","unstructured":"Winans SA, Luce AM, Hasbun R. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone. Infection [Internet] 2013 19;41:769\u201374. http:\/\/link.springer.com\/10.1007\/s15010-013-0477-0d.10.1007\/s15010-013-0477-0","DOI":"10.1007\/s15010-013-0477-0"},{"key":"4575_CR21","doi-asserted-by":"crossref","unstructured":"Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South. Med. J. [Internet] 2005;98:590\u20135. http:\/\/sma.org\/southern-medical-journal\/article\/evaluation-of-the-efficacy-and-safety-of-outpatient-parenteral-antimicrobial-therapy-for-infections-with-methicillin-sensitive-staphylococcus-aureusd.10.1097\/01.SMJ.0000145300.28736.BB","DOI":"10.1097\/01.SMJ.0000145300.28736.BB"},{"key":"4575_CR22","doi-asserted-by":"crossref","unstructured":"Mohamed A, Bennett N, Ploetz J, Aragon L, Kennedy K, Boyd S. Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia. Int. J. Antimicrob. Agents [Internet] 2022;60:106632. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922001443d.10.1016\/j.ijantimicag.2022.106632","DOI":"10.1016\/j.ijantimicag.2022.106632"},{"key":"4575_CR23","doi-asserted-by":"crossref","unstructured":"Kang N, Housman S, Nicolau D. Assessing the surrogate susceptibility of oxacillin and cefoxitin for commonly utilized parenteral agents against methicillin-susceptible Staphylococcus aureus: Focus on ceftriaxone discordance between predictive susceptibility and in vivo exposures. Pathogens [Internet] 2015 30;4:599\u2013605. http:\/\/www.mdpi.com\/2076-0817\/4\/3\/599d.10.3390\/pathogens4030599","DOI":"10.3390\/pathogens4030599"},{"key":"4575_CR24","doi-asserted-by":"crossref","unstructured":"Phe K, Dao D, Palmer HR, Tam VH. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. [Internet] 2015;59:1370\u20131370. https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04531-14d.10.1128\/AAC.04531-14","DOI":"10.1128\/AAC.04531-14"},{"key":"4575_CR25","doi-asserted-by":"crossref","unstructured":"O\u2019Brien JM, Lu B, Ali NA, Levine DA, Aberegg SK, Lemeshow S. Insurance type and sepsis-associated hospitalizations and sepsis-associated mortality among US adults: a retrospective cohort study. Crit. Care [Internet] 2011 23;15:R130. https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc10243d.10.1186\/cc10243","DOI":"10.1186\/cc10243"},{"key":"4575_CR26","doi-asserted-by":"crossref","unstructured":"Moore JX, Donnelly JP, Griffin R, Howard G, Safford MM, Wang HE. Defining sepsis mortality clusters in the United States*. Crit. Care Med. [Internet] 2016;44:1380\u20137. http:\/\/journals.lww.com\/00003246-201607000-00015d.10.1097\/CCM.0000000000001665","DOI":"10.1097\/CCM.0000000000001665"},{"key":"4575_CR27","doi-asserted-by":"crossref","unstructured":"Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC. Racial variation in the incidence, care, and outcomes of severe sepsis. Am. J. Respir. Crit. Care Med. [Internet] 2008 1;177:279\u201384. https:\/\/www.atsjournals.org\/doi\/10.1164\/rccm.200703-480OCd.10.1164\/rccm.200703-480OC","DOI":"10.1164\/rccm.200703-480OC"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04575-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T11:09:32Z","timestamp":1678360172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04575-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4575"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04575-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our internal institutional review board reviewed the study protocol and granted it an exempt status (#19-005199).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}